9 January 2017 - Second priority review granted for Tecentriq in advanced bladder cancer.

​Roche today announced that the U.S. FDA has accepted the company’s supplemental biologics license application and granted priority review for Tecentriq (atezolizumab) for the treatment of people with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin chemotherapy, and are either previously untreated (first-line) or have disease progression at least 12 months after receiving chemotherapy before surgery (neoadjuvant) or after surgery (adjuvant). 

Urothelial carcinoma accounts for 90% of all bladder cancers and can also be found in the renal pelvis, ureter and urethra.

Read Roche press release